BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

...builds out its preclinical data package for its lead antibody candidates against S100A4, S100A7 and S100P... pancreatic cancer mouse models. Lykera reported results from preclinical work on its third target, S100P...
...Programmed cell death 1 ligand 1 RAGE - Receptor for advanced glycation endproducts S100P - S100 calcium binding protein P...
BioCentury | Sep 19, 2019
Distillery Therapeutics

S100A10 and SP1 identified as ALS targets

DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) Inhibiting the adaptor protein S100A10 or SP1, a transcription factor that controls S100A10 expression, could treat ALS and injury-induced motor neuron degeneration. In mice with ALS, siRNA...
BioCentury | Sep 10, 2019
Distillery Therapeutics

S100A9 could normalize metabolic imbalances from insulin deficiency

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Promoting expression of S100A9, a plasma protein induced by leptin, could treat diabetes. Type I and Type II diabetes induce insulin deficiency, which causes metabolic imbalances including hyperglycemia, hyperglucagonemia, hyperketonemia,...
BioCentury | Aug 10, 2018
Clinical News

Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in the...
BioCentury | Mar 2, 2018
Clinical News

Glenmark reports Phase IIa data for anti-OX40 mAb in atopic dermatitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a placebo-controlled Phase IIa trial in over 60 patients with moderate to severe atopic dermatitis showing that GBR 830 reduced mRNA biomarkers of disease activity, including S100...
BioCentury | Dec 8, 2017
Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg oral laquinimod (SAIK-MS) missed the primary endpoint of reducing brain atrophy on MRI as measured by percent brain volume change from baseline to week 48 compared to...
BioCentury | Oct 5, 2017
Translation in Brief

SSRIs' first responders

Researchers at The Rockefeller University have identified a role for CCK-expressing neurons in initiating responses to SSRIs for depression and manipulated the neurons to recapitulate the drugs' effects. The findings could lead to faster-acting antidepressants...
BioCentury | Aug 29, 2017
Distillery Therapeutics


INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting S100A4 or depleting S100A4-expressing cells could help treat glioblastoma multiforme (GBM) and other gliomas. In samples from glioma patients, high tumor levels of...
BioCentury | Aug 3, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jul 18, 2017
Distillery Techniques


TECHNOLOGY: Tissue markers Tumor levels of S100A10 , S100A11 and TNC mRNAs could help predict survival in lung cancer. In 57 lung adenocarcinoma patients, mRNA levels of S100A10, S100A11 and TNC were higher in tumors than...
Items per page:
1 - 10 of 99